These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 15878055)

  • 21. Methotrexate treatment for sarcoid-associated panuveitis.
    Dev S; McCallum RM; Jaffe GJ
    Ophthalmology; 1999 Jan; 106(1):111-8. PubMed ID: 9917790
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
    Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
    J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experience with single-dose daclizumab in the prevention of acute rejection in heart transplantation.
    Cuppoletti A; Perez-Villa F; Vallejos I; Roig E
    Transplant Proc; 2005 Nov; 37(9):4036-8. PubMed ID: 16386620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis.
    Pavesio C; Zierhut M; Bairi K; Comstock TL; Usner DW;
    Ophthalmology; 2010 Mar; 117(3):567-75, 575.e1. PubMed ID: 20079922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine.
    Sloper CM; Powell RJ; Dua HS
    Ophthalmology; 1999 Apr; 106(4):723-8. PubMed ID: 10201592
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravitreal infliximab for sight-threatening relapsing uveitis in Behçet disease: a pilot study in 15 patients.
    Markomichelakis N; Delicha E; Masselos S; Sfikakis PP
    Am J Ophthalmol; 2012 Sep; 154(3):534-541.e1. PubMed ID: 22789563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
    Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
    Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.
    Nussenblatt RB; Fortin E; Schiffman R; Rizzo L; Smith J; Van Veldhuisen P; Sran P; Yaffe A; Goldman CK; Waldmann TA; Whitcup SM
    Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7462-6. PubMed ID: 10377437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions.
    Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL
    Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
    Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
    Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.
    Dick AD; Tugal-Tutkun I; Foster S; Zierhut M; Melissa Liew SH; Bezlyak V; Androudi S
    Ophthalmology; 2013 Apr; 120(4):777-87. PubMed ID: 23290985
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease.
    Wroblewski K; Sen HN; Yeh S; Faia L; Li Z; Sran P; Gangaputra S; Vitale S; Sherry P; Nussenblatt R
    Can J Ophthalmol; 2011 Aug; 46(4):322-8. PubMed ID: 21816251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
    Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
    Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.
    Sen HN; Levy-Clarke G; Faia LJ; Li Z; Yeh S; Barron KS; Ryan JG; Hammel K; Nussenblatt RB
    Am J Ophthalmol; 2009 Nov; 148(5):696-703.e1. PubMed ID: 19664754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes.
    Suhler EB; Smith JR; Wertheim MS; Lauer AK; Kurz DE; Pickard TD; Rosenbaum JT
    Arch Ophthalmol; 2005 Jul; 123(7):903-12. PubMed ID: 16009830
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined fluocinolone acetonide intraocular delivery system insertion, phacoemulsification, and intraocular lens implantation for severe uveitis.
    Chieh JJ; Carlson AN; Jaffe GJ
    Am J Ophthalmol; 2008 Oct; 146(4):589-594. PubMed ID: 18639220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients.
    Díaz-Llopis M; Salom D; Garcia-de-Vicuña C; Cordero-Coma M; Ortega G; Ortego N; Suarez-de-Figueroa M; Rio-Pardo MJ; Fernandez-Cid C; Fonollosa A; Blanco R; Garcia-Aparicio AM; Benitez-Del-Castillo JM; Olea JL; Arevalo JF
    Ophthalmology; 2012 Aug; 119(8):1575-81. PubMed ID: 22525047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study.
    Lopez-Gonzalez R; Loza E; Jover JA; Benitez Del Castillo JM; Mendez R; Hernandez-Garcia C; Pato E
    Scand J Rheumatol; 2009; 38(1):58-62. PubMed ID: 18991187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction.
    Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L;
    Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis.
    Tanner V; Kanski JJ; Frith PA
    Eye (Lond); 1998; 12 ( Pt 4)():679-85. PubMed ID: 9850264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.